Roche oral drug shown to keep breast cancer at bay, boosting shares
By Ludwig Burger FRANKFURT (Reuters) -Roche's (ROG.SW) experimental oral drug giredestrant has been shown to cut the risk of recurrence of a common form of breast cancer after surgery, boosting the company's shares and underpinning its …